Bioventus Inc. (BVS) stock forecast and price target
Price $10.66 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($10.66)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $0.77 | +12.9% | $595M |
| Next fiscal year ends December 31, 2027 | $0.89 | +15.6% | $633M |
| Next quarter ends December 31, 2026 | $0.24 | −1.7% | $166M |
| Quarter after ends March 31, 2027 | $0.15 | +0.0% | $139M |
Consensus of the analysts covering Bioventus, updated daily. In the last 30 days 0 estimates were raised and 1 lowered.
Our model vs. Wall Street
Analysts see 55.7% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Bioventus’s intrinsic value about 50% below today’s market value, and it scores 1.8 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Bioventus stock price target?
The average 12-month target from 5 analysts is $16.60, 55.7% above the current price of $10.66 Targets range from $15.00 to $18.00.
Is Bioventus a buy according to analysts?
The consensus rating is “Strong buy” (2 strong buy, 3 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Bioventus expected to earn?
Analysts expect EPS of $0.77 for the fiscal year ending December 31, 2026 and $0.89 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.